Compare Expedia Group Inc (EXPE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs GSK plc — how do they compare? Expedia Group Inc trades at $321.51 (market cap $38.53B), while GSK plc trades at $50.45 (market cap $102.60B). The key difference: GSK plc is far larger — about 2.7× Expedia Group Inc's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| EXPE | GSK | |
|---|---|---|
Market Cap | $38.53B | $102.60B |
Sector | Consumer Cyclical | Health |
52-Week High | $321.07 | $61.18 |
52-Week Low | $188.51 | $38.22 |
Enterprise Value | $37.09B | $123.04B |
Dividend Yield | 0.6% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $321.5, up 2.39% today, with strong technical momentum and a bullish moving average crossover. The company reported robust Q2 2026 earnings, beating estimates with EPS of $5.76 versus $5.22 expected, driven by 14% revenue growth and record adjusted EBITDA of $1.1 billion (Business Wire, 2026-08-05). Fundamentals show high profitability with a 90.43% gross margin and improving net income, while valuation ratios like P/E of 20.19 and P/S of 2.59 reflect market confidence.
Outlook is positive with raised full-year revenue guidance to $16.05B-$16.22B (WSJ, 2026-08-05), supported by AI and B2B growth. Risks include competitive pressures and economic sensitivity. Analysts are mixed but lean bullish with a $322.95 consensus target, near the current price, suggesting limited upside but stability.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
